Hardly a Hallucination: Visions for the Psychedelic Medicine Industry Set to Materialize in 2021

A look back at where we’ve been and what’s to come

  • Psilocybin-therapy company COMPASS Pathways raised over $140 million through its IPO.
  • Thiel Capital, founded by renowned billionaire investor Peter Thiel, backed psychedelic drug development company ATAI Life Sciences in its $215 million Series C round. The company is set to go public sometime in the spring of 2021.
  • The Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation completed data analysis of the first of two FDA Phase 3 trials of MDMA-assisted therapy for the treatment of PTSD. The results confirmed those of Phase 2 that demonstrated marked improvement.
Psychedelic-assisted Psychotherapy
  • Oregon became the first US state to decriminalize the use of psilocybin mushrooms and other psychedelic substances. Moreover, psilocybin was legalized for its use in mental health treatment in supervised settings.
  • The University of California at Berkeley announced the launch of the UC Berkeley Center for the Science of Psychedelics. The university will join a worldwide cohort of elite academic institutions with research centers dedicated to this field.
  • The Conscious Fund, in conjunction with MicroDose, hosted the largest virtual psychedelics conference to date.
  • A collaboration of scientists at Stanford University and The University of North Carolina at Chapel Hill, for the first time, solved the high-resolution structure of psychedelics when they are actively bound to serotonin receptors on the surface of brain cells.

--

--

Investing in global early-stage ventures in psychedelic medicine, helping deliver better outcomes for mental health, addiction, and pain.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
The Conscious Fund

Investing in global early-stage ventures in psychedelic medicine, helping deliver better outcomes for mental health, addiction, and pain.